Relates to Heterocyclic compounds of formula (i) wherein X and x are each CH, CR1 or N and are each CH, CR2 or n, where R1 and R2 are each compounds of formula (a), (b), among others, where R3 is H, cn or Halo R4 is H, alkyl, etc. R5 is H OR - C (o) R6, wherein R6 is alkoxy, Arilalcoxi, alkyl, cycloalkyl, among others.Preferred compounds are: (naftalendiilbis (2.7 - 1H benzimidazole - 5.2 - diyl pirrolidinadiil (2S) - 2.1 - ((1R) - 2 - oxo - 1 - phenyl - 2.1 - biscarbamato ethandiylbisoxybismethanol) dimethyl ((1S, 2R) - 2 - methoxy - (1 - ((1R, 3S, 5R) - 3 - (4 - (4 - (4 - (2 - ((1R, 3S, 5R) - 2 - (N - (Methoxycarbonyl) - O - methyl - L - treonil) - 2-azabicyclo [3.1.0] hex - 3 - yl) - 1H imidazole - 4 - il) phenyl) - 2 - naphthyl) - 1H imidazole - 2 - il) - 2-azabicyclo [3.1.0] hex - 2 - il) carbonyl) propyl carbamate) methyl (1R) - 2 - ((2S) - 2 - (5 - (6 - (2 - (2 - ((2S) - 1 - ((2R) - 2 - (dimethylamino) - 2 - (phenylacetyl) 2 - pirrolidinil) - 1H benzimidazole) - il - 6 - 2 - naphthyl) - 1h-benzimidazol-2 - yl) - 1 - pirrolidinil) - n, N - dimethyl - 2 - oxo - 1 - feniletanamina among others. It also relates to a Pharmaceutical composition.These compounds are inhibitors of the NS5A Protein encoded by hepatitis C virus being useful in the treatment of hepatitis CSE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE X Y X SON CADA UNO CH, CR1 O N Y E Y SON CADA UNO CH, CR2 O N, DONDE R1 Y R2 SON CADA UNO COMPUESTOS DE FORMULA (a), (b), ENTRE OTROS, EN DONDE R3 ES H, CN O HALO R4 ES H, ALQUILO, ENTRE OTROS R5 ES H O -C(O)R6, EN DONDE R6 ES ALCOXI, ALQUILO, ARILALCOXI, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (2,7-NAFTALENDIILBIS(1H-BENCIMIDAZOL-5,2-DIIL(2S)-2,1-PIRROLIDINADIIL((1R)-2-OXO-1-FENIL-2,1-ETANODIIL)))BISCARBAMATO DE DIMETILO ((1S,2R)-2-METOXI-1-(((1R,3S,5R)-3-(4-(6-(4-(2-((1R,3S,5R)-2-(N-(METOXICARBONIL)-O-METIL-L-TREONIL)-2-AZABICICLO[3.1.0]HEX-3-IL)-1H-IMIDAZOL-4-IL)FENIL)-2-NAFTIL)-1H-IMIDAZOL-2-IL)-2-AZABICICLO[3.1.0]HEX-2-IL)CAR
